

Gynecology Oncology (GynOnc) Disease-Oriented Team

Clinical Research Treatment Trial Flowchart



PLATINUM-RESISTANT

GOG-3076

Platinum Doublet + Bevacizumab +/-OlviVec
>3L
PI: Tewari
CRC: Jiana Ejbara

Accrual: 5/5

ETCTN 10422

Abemaciclib + Olaparib
PI: Dwabe
CRC: Jiana Ejbara

Accrual: 0/5

NEWLY DIAGNOSED

GOG-3135

GSK5733584 +/- Bevacizumab
HR proficient
PI: Tewari
CRC: Jiana Ejbara

Accrual: 0/5

PLATINUM-SENSITIVE

GOG-3136

GSK5733584 + Bevacizumab Vs. Platinum
doublet + Bevacizumab
PI: Tewari
CRC: Jiana Ejbara

Accrual: 0/5



■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

UCI 26-14

Raludotatug Deruxtecan

High-Grade Serous

PI: Tewari

CRC: Jiana Ejbara

Accrual: 0/5

UCI 26-68

Intraoperative Tumor Fluorescence + Cytalux

PI: Tseng

CRC: Jiana Ejbara

Accrual: 0/3



GOG-3123

Sacituzumab Tirumotecan + Pembrolizumab +/-
Bevacizumab VS. SOC

1L Maintenance

PI: Tewari

CRC: Jiana Ejbara

Accrual: 0/5

NRG-GY037

Chemoradiation with pembro, followed by
pembro maintenance +/- induction therapy of
chemo & pembro

No prior treatment

PI: Healy

CRC: Jiana Ejbara

Accrual: 2/5



Endometrial

GOG 3119

Pembro +/- Sacituzumab Tirumotecan
 For pMMR
 1L or 1 prior
 PI: Tseng
 CRC: Jiana Ejbara

Accrual: 3/5

NRG-GY026

Carbo/Taxol +/- Trastuzumab/hyaluronidase or
 pertuzumab/trastuzumab/hyaluronidase
 For HER2 +
 No prior treatment
 PI: Tewari
 CRC: Jiana Ejbara

Accrual: 0/5

GOG 3110

AZD8205 (ADC) vs. Physicians Choice for B7-H4
 positive endo
 ≤ 2 prior lines
 PI: Tseng
 CRC: Jiana Ejbara

Accrual: 0/5

GOG 3128

Rinatabart Sesutecan

PI: Tewari
 CRC: Jiana Ejbara

Accrual: 0/6



UCI 24-146

REGN5668 + REGN4018 or Cemiplimab
Endometrial or ovarian (SLOT RSVP REQ)

PI: Tseng
CRC: Jiana Ejbara

Accrual: 2/5

UCI 24-142

VET3-TGI +/- Atezolizumab

PI: Uchio
CRC: Jiana Ejbara

Accrual: 2/5

UCI 24-08

SPEDOX-6 for 2L+ cervical, uterine or ovarian
SLOT RSVP REQ

PI: Chow
CRC: Jiana Ejbara

Accrual: 8/25

UCI 24-176

Raludotatug Deruxtecan
Endometrial, Ovarian, & Cervical
SLOT RSVP REQ

PI: Mar
CRC: Jiana Ejbara

Accrual: 0/5



UCI 26-60

ASP546C

CLDN18.2

PI: Dayyani

CRC: TBA

Accrual: 0/5

UCI 25-194

PLX-61639

SMARCA4

PI: Villalona-Calero

CRC: Jiana Ejbara

Accrual: 0/5



UCI 24-05

Riluzole PO vs. Placebo PO
Perceived worsening of cognitive function
CRC: Jiana Ejbara
Accrual: 26/39